idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura)-pipeline review, h2 2017

idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura)-pipeline review, h2 2017


  • Products Id :- GMDHC9639IDB
  • |
  • Pages: 120
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 5, 8, 3, 2 and 7 respectively.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).

-The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Overview 6

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Companies Involved in Therapeutics Development 22

3SBio Inc 22

Amgen Inc 22

arGEN-X BV 23

Biogen Inc 23

Boehringer Ingelheim GmbH 24

Bristol-Myers Squibb Company 24

CSL Ltd 25

Dova Pharmaceuticals Inc 25

Enzene Biosciences Ltd 26

Genosco Inc 26

GlaxoSmithKline Plc 27

Hansa Medical AB 27

Immunomedics Inc 28

Intas Pharmaceuticals Ltd 28

Jiangsu Hengrui Medicine Co Ltd 29

Momenta Pharmaceuticals Inc 30

Novartis AG 31

Pfizer Inc 32

Pharmagenesis Inc 32

Protalex Inc 33

Rigel Pharmaceuticals Inc 33

UCB SA 34

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Drug Profiles 35

avatrombopag-Drug Profile 35

belimumab-Drug Profile 38

BI-655064-Drug Profile 46

efgartigimod alfa-Drug Profile 48

eltrombopag olamine-Drug Profile 51

eltrombopag olamine-Drug Profile 58

fostamatinib disodium-Drug Profile 59

GL-2045-Drug Profile 65

Hetrombopag Olamine-Drug Profile 67

KLM-465-Drug Profile 68

letolizumab-Drug Profile 70

M-230-Drug Profile 71

M-254-Drug Profile 72

M-281-Drug Profile 73

PBF-1650-Drug Profile 74

PHN-013-Drug Profile 75

PRTX-100-Drug Profile 76

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases-Drug Profile 83

rituximab-Drug Profile 84

romiplostim-Drug Profile 91

romiplostim biosimilar-Drug Profile 95

romiplostim biosimilar-Drug Profile 96

rozanolixizumab-Drug Profile 97

SKIO-703-Drug Profile 98

thrombopoietin-Drug Profile 100

veltuzumab-Drug Profile 101

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects 105

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products 106

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Product Development Milestones 107

Featured News & Press Releases 107

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by 3SBio Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Amgen Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by arGEN-X BV, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Biogen Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Bristol-Myers Squibb Company, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by CSL Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Dova Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Enzene Biosciences Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Genosco Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by GlaxoSmithKline Plc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Hansa Medical AB, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Immunomedics Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Momenta Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Novartis AG, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pfizer Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pharmagenesis Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Protalex Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by UCB SA, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3SBio Inc

Amgen Inc

arGEN-X BV

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CSL Ltd

Dova Pharmaceuticals Inc

Enzene Biosciences Ltd

Genosco Inc

GlaxoSmithKline Plc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

select a license
Single User License
USD 2000 INR 142440
Site License
USD 4000 INR 284880
Corporate User License
USD 6000 INR 427320

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com